{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fang Y"],"funding":["National Natural Science Foundation of China"],"pagination":["10333-10345"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9078890"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(19)"],"pubmed_abstract":["Focal adhesion kinase (FAK) has been identified as a promising target in the early diagnosis and therapy of tumor. In this work, we obtained and evaluated another two novel pyrimidine-based F-18 labeled tumor imaging agents targeting FAK. Among them, the corresponding F-19 standards [<sup>19</sup>F]2, displayed inhibition of FAK with IC<sub>50</sub> values of 57.1 nM (better than the results in our published work) and showed an good selectivity profile against some other kinds of cancer-related kinases. [<sup>18</sup>F]2 also had relatively good results in the <i>in vivo</i> biodistribution in S180-tumor-bearing mice, with tumor uptake of 5.40 ± 0.12 and 5.96 ± 0.09 % ID per g at 15 and 30 min post-injection, respectively. What's more, [<sup>18</sup>F]2 could be accumulated in tumor at 30 "],"journal":["RSC advances"],"pubmed_title":["Preparation, <i>in vitro</i> and <i>in vivo</i> evaluation, and molecular dynamics (MD) simulation studies of novel F-18 labeled tumor imaging agents targeting focal adhesion kinase (FAK)."],"pmcid":["PMC9078890"],"funding_grant_id":["21371026"],"pubmed_authors":["Fang Y","Li X","Liu J","Zhang J","Wang D","Xue Q","Zhang H","Dava G","Wang H","Xu X"],"additional_accession":[]},"is_claimable":false,"name":"Preparation, <i>in vitro</i> and <i>in vivo</i> evaluation, and molecular dynamics (MD) simulation studies of novel F-18 labeled tumor imaging agents targeting focal adhesion kinase (FAK).","description":"Focal adhesion kinase (FAK) has been identified as a promising target in the early diagnosis and therapy of tumor. In this work, we obtained and evaluated another two novel pyrimidine-based F-18 labeled tumor imaging agents targeting FAK. Among them, the corresponding F-19 standards [<sup>19</sup>F]2, displayed inhibition of FAK with IC<sub>50</sub> values of 57.1 nM (better than the results in our published work) and showed an good selectivity profile against some other kinds of cancer-related kinases. [<sup>18</sup>F]2 also had relatively good results in the <i>in vivo</i> biodistribution in S180-tumor-bearing mice, with tumor uptake of 5.40 ± 0.12 and 5.96 ± 0.09 % ID per g at 15 and 30 min post-injection, respectively. What's more, [<sup>18</sup>F]2 could be accumulated in tumor at 30 ","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Mar","modification":"2026-05-30T18:48:48.753Z","creation":"2024-12-04T03:40:39.669Z"},"accession":"S-EPMC9078890","cross_references":{"pubmed":["35540451"],"doi":["10.1039/c8ra00652k"]}}